Cell lines

CD8+ CTL

Preparation Method

Cells were cultured in the RPMI 1640 medium supplemented with 10% (v/v) FCS and 5% (v/v) culture supernatant of rat spleen cells.

Reaction Conditions

Cells were stimulated with 5 μg/ml of concanavalin A for 24 h.

Applications

Concanavalin A treatment could preferentially decrease the cell viability of CD8+ population prepared from the immunized mice. A certain group(s) of CD8+ population in the immunized mice might be highly susceptible to concanavalin A. The activation through T cell receptors, especially PKC activation, increases the sensitivity of CD8++ CTL to concanavalin A.

Concanamycin A belongs to the concanamycins, a family of macrolide antibiotics isolated from Streptomyces diastatochromogenes that are highly active and selective inhibitors of the vacuolar proton-ATPase (v-[H^[+]]ATPase). Among them, concanamycin A is the most selective and potent inhibitor of the V-[H^[+]]ATPase.^[1]

n vitro study indicated that concanamycin A was active at 5 nM and completely blocked influenza virus infection at 10 nM in MDCK cells. Results showed that concanamycin A blocked viral replication by inhibiting the v-[H^[+]]ATPase, thus preventing acidification of endosomes and release of virions into the cytoplasm. An early event in virus infection is the target of concanamytin A. In addition, the inhibition of the v-[H^[+]]ATPase by concanamycin A prevents endosomal acidification, inhibiting virus release from endosomes.^[1]

References:
[1].Rosario G. et al. Concanamycin A blocks influenza virus entry into cells under acidic conditions. FEBS Letters 1994 June; 349; 327-330.